Physician
Vandyke, Charles
Vandyke, Charles was paid $422K by Medicaid between Jan 2018 and Sep 2021, across 12 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 51% of everything it billed.
33Billing provider infoVANDYKE, CHARLES
PEKIN, IL 61554
PEKIN, IL 61554
33aNPI1396837662assigned 09/28/2006
33bProvider typeEmergency Medicine Physician
28Total paid$422K
24GClaims12,367
24DCodes billed12
24AFirst – last monthJan 2018 – Sep 2021
Compared with peers
Next to other Emergency Medicine Physician providers in Illinois
Rank by total paid#224 of 1,980
Median peer was paid$150K
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,126 | $79K | |
| 2019 | 6,324 | $209K | |
| 2020 | 3,421 | $112K | |
| 2021 | 496 | $22K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 51% | 5,174 | 4,696 | $217K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 29% | 1,837 | 1,657 | $121K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 6.6% | 1,811 | 1,624 | $28K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.6% | 473 | 428 | $20K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.2% | 568 | 541 | $13K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.8% | 381 | 333 | $12K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 134 | 125 | $4K |
| 81002 | <1% | 1,084 | 1,012 | $3K | |
| 81025 | <1% | 764 | 710 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 55 | 41 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 72 | 64 | $1K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | 12 | $1.65 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.